DIA Annual Meeting Highlights End of Paper-
Based Systems via SAFE-BioPharma Industry
Media, Others Invited to Expert Briefing on Legal Advantages of Digital Signatures Over Other Types
of Electronic Signatures
June 09, 2010 09:17 AM Eastern Daylight Time
FT. LEE, N.J.--(EON: Enhanced Online News)--Examples of how the SAFE-BioPharma® industry standard is
helping the biopharmaceutical and healthcare communities become paperless are being featured during the annual
meeting of the Drug Information Association (DIA), June 13-17 in Washington, D.C.
A special briefing about the important differences in legal protection between digital signatures and other types of
electronic signatures will be made by Randy Sabett, nationally recognized privacy and data security legal authority
and partner, Sonnenschein Nath & Rosenthal LLP (D.C. office). Mr. Sabett is a Commissioner for the Commission
on Cyber Security for the 44th Presidency and an adjunct professor at George Washington University. (12:30 p.m.–
1:30 p.m., Wednesday, June 16, DIA Press Room).
The SAFE-BioPharma standard is used to verify and manage digital identities involved in electronic transactions and
to apply digital signatures to electronic documents.
Session details follow:
Global Electronic Submissions: Regulators and Company Explain How Digital Signatures Make Them
Possible – Gary M. Gensinger, Food and Drug Administration, and Timothy Buxton, European Medicines Agency,
will discuss their perspectives on the growing use of electronic receipt and review. Peter Loupos, sanofi-aventis, will
report on use of SAFE-BioPharma digital signatures to sign esubmissions to FDA and EMA. Session chair Mollie
Shields-Uehling, SAFE-BioPharma, will describe purpose of SAFE-BioPharma standard (3:30 p.m., Wednesday,
June 16, Room 202A, Session #398)
Electronic Laboratory Notebooks: Perspectives from Three Biopharmaceutical Companies – Jay
Stevenson, Bristol-Myers Squibb, Anna Elizabeth Plappert, sanofi-aventis, and Michael Lavoie, Pf